Robert Ford
American businessman
Robert B. Ford is an American businessman, and the chief executive officer and chairman of Abbott Laboratories, a publicly traded medical devices and health care company based in Abbott Park, Illinois. He received a bachelor's degree from Boston College and an MBA from Haas School of Business.2
From Wikipedia’s article on Robert Ford (this version), CC BY-SA 4.0.
Companies
- Abbott LaboratoriesChair Feb 23, 2022 to now11
- Abbott LaboratoriesChief executive officer 2020 to now12
- Abbott LaboratoriesBoard member 2019 to now12
- Abbott LaboratoriesPresident Feb 26, 2019 to Jul 2, 202113
- Abbott LaboratoriesChief operating officer Feb 26, 2019 to Mar 3, 202013
- Abbott LaboratoriesSenior Vice President Jul 3, 2014 to Jun 5, 201814
Holdings
Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.
Shares held
Abbott Laboratories ABT522,664 shares15$54.8M at $104.87Aug 27, 2026
As of each latest filing. The line shows shares held over time.
Recent filings
- Aug 25, 2026Sold 180,297 shares at $116.19 of Abbott Laboratories15
- Aug 25, 2026Sold 218,535 shares at $115.57 of Abbott Laboratories15
- Aug 25, 2026Exercised options 246,963 shares at $59.94 of Abbott Laboratories15
- Aug 25, 2026Exercised options 151,869 shares at $44.40 of Abbott Laboratories15
- Feb 27, 2026Shares withheld for tax 30,308 shares at $116.26 of Abbott Laboratories16
- Feb 24, 2026Granted 83,464 shares of Abbott Laboratories17
- Jan 23, 2026Bought 18,800 shares at $107.13 of Abbott Laboratories18
- Feb 28, 2025Shares withheld for tax 31,651 shares at $135.87 of Abbott Laboratories19
- Feb 25, 2025Granted 64,897 shares of Abbott Laboratories20
- Feb 5, 2025Sold 285,388 shares at $131.17 of Abbott Laboratories21
- Feb 5, 2025Exercised options 285,388 shares at $38.40 of Abbott Laboratories21
- Sep 12, 2024Sold 61,380 shares at $116.90 of Abbott Laboratories22
- Sep 12, 2024Sold 80,299 shares at $116.04 of Abbott Laboratories22
- Sep 12, 2024Exercised options 14,243 shares at $48.90 of Abbott Laboratories22
- Sep 12, 2024Exercised options 127,436 shares at $47.00 of Abbott Laboratories22
- Feb 29, 2024Shares withheld for tax 31,610 shares at $120.05 of Abbott Laboratories23
- Feb 21, 2024Granted 70,332 shares of Abbott Laboratories24
- Feb 28, 2023Shares withheld for tax 30,742 shares at $99.77 of Abbott Laboratories25
- Feb 17, 2023Granted 70,008 shares of Abbott Laboratories26
- Aug 25, 2022Sold 102,425 shares at $105.10 of Abbott Laboratories27
- Aug 25, 2022Exercised options 56,933 shares at $41.14 of Abbott Laboratories27
- Aug 25, 2022Exercised options 45,492 shares at $39.12 of Abbott Laboratories27
- Mar 25, 2022Gift 33,414 shares of Abbott Laboratories28
- Mar 25, 2022Gift 33,414 shares of Abbott Laboratories28
- Feb 28, 2022Shares withheld for tax 26,579 shares at $122.41 of Abbott Laboratories29
Early life and education
Career
Occupation: business executive.9
- Since 2020Chief executive officer5 8
- Since 2020Chief executive, Abbott Laboratories6
- Since 2019Board member, Abbott Laboratories7
- Since 1996Worked at Abbott Laboratories4 5
- Date not recordedWorked at Becton Dickinson4
Ford joined Abbott in 1996 within its diabetes care business, later heading the company's medical device businesses, and Abbott's integration of St. Jude Medical in 2017, its largest acquisition at the time. He was named president and COO in October 2018.
In March 2020, Ford became the chief executive officer of Abbott. He stated that the sale of medical devices such as FreeStyle Libre and diagnostics would be prioritized as well as developing technology to monitor consumer health through smartphones and other connected devices.
At the beginning of the COVID-19 pandemic, Ford led the company's COVID-19 testing development and distribution. He pulled Abbott's scientists and manufacturing teams off their projects to work on four teams, each focused on specific tests. The company introduced its first two tests in March 2020 and delivered more than 400 million in 2020. Ford said he considers Abbott's BinaxNOW test to be a model, setting a trend for rapid point-of-care testing after the coronavirus pandemic for ailments such as influenza, sexually transmitted diseases, and hepatitis. In April 2020, Chief Executive recognized Ford for Abbott's response to accessibility for testing.
In December 2021, Ford became Abbott's chairman as well as CEO.
From Wikipedia’s article on Robert Ford (this version), CC BY-SA 4.0.
Personal life
- CitizenshipUnited States10
Links
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataRobert Ford on Wikidata
- 2WikipediaRobert Ford on Wikipedia
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARAbbott Laboratories, Chair
- 12Wikidata and SEC EDGARAbbott Laboratories, Chief executive officer
- 13SEC EDGARAbbott Laboratories, President
- 14
- 15
- 16SEC EDGARForm 4 filed Mar 3, 2026
- 17SEC EDGARForm 4 filed Feb 26, 2026
- 18SEC EDGARForm 4 filed Jan 26, 2026
- 19SEC EDGARForm 4 filed Mar 4, 2025
- 20SEC EDGARForm 4 filed Feb 27, 2025
- 21SEC EDGARForm 4 filed Feb 7, 2025
- 22SEC EDGARForm 4 filed Sep 13, 2024
- 23SEC EDGARForm 4 filed Mar 4, 2024
- 24SEC EDGARForm 4 filed Feb 23, 2024
- 25SEC EDGARForm 4 filed Mar 2, 2023
- 26SEC EDGARForm 4 filed Feb 22, 2023
- 27SEC EDGARForm 4 filed Aug 26, 2022
- 28SEC EDGARForm 4 filed Apr 1, 2022
- 29SEC EDGARForm 4 filed Mar 2, 2022